CSF / BODY FLUIDS ANALYSIS FOR HEMATOLOGIC MALIGANCIES

The CSF / BODY FLUIDS ANALYSIS FOR HEMATOLOGIC MALIGNANCIES is a specialized cytological and laboratory diagnostic test used to detect the presence of malignant (cancerous) cells in cerebrospinal fluid (CSF) or other body fluids such as pleural fluid, ascitic fluid, or pericardial fluid.

This test plays a crucial role in diagnosing and monitoring hematological cancers, including leukemia, lymphoma, and other metastatic malignancies that may spread to the central nervous system or body cavities.

The collected fluid sample is carefully examined under a microscope using cytological staining techniques to identify abnormal or cancerous cells.

Benefits of the Test

• Detects malignant cells in CSF and body fluids
• Helps diagnose spread of leukemia and lymphoma
• Assists in cancer staging and prognosis
• Guides treatment planning and therapy response
• Detects central nervous system involvement in blood cancers
• Supports early identification of metastatic disease

Why Doctors Recommend This Test

Doctors recommend CSF or body fluid cytology when there is suspicion that cancer has spread beyond its primary site. It is commonly used in patients with neurological symptoms, unexplained fluid accumulation, or known hematologic malignancies.

This test is essential for evaluating disease progression, especially in leukemia and lymphoma cases where cancer cells may invade the brain, spinal cord, or body cavities.

Preparation Before Test

• No fasting required in most cases
• Procedure depends on type of fluid collection (lumbar puncture or aspiration)
• Inform doctor about medications, especially blood thinners
• Follow sterile procedure guidelines strictly
• Rest may be advised after CSF collection

Normal Reporting Time

Results are typically available within 24 to 72 hours, depending on laboratory processing and additional staining requirements.

Who Should Take This Test

• Patients with suspected or confirmed leukemia
• Individuals with lymphoma requiring staging
• Patients with unexplained neurological symptoms
• Cases with pleural, ascitic, or pericardial effusion
• Suspected metastatic cancer cases
• Patients under oncology evaluation or follow-up